• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2015 Fiscal Year Final Research Report

Role of CD26 molecule in the infection of MERS(Middle East respiratory syndrome) virus and development of new therapy

Research Project

  • PDF
Project/Area Number 26670486
Research Category

Grant-in-Aid for Challenging Exploratory Research

Allocation TypeMulti-year Fund
Research Field Infectious disease medicine
Research InstitutionJuntendo University

Principal Investigator

MORIMOTO CHIKAO  順天堂大学, 医学(系)研究科(研究院), 客員教授 (30119028)

Co-Investigator(Kenkyū-buntansha) IWATA Satoshi  順天堂大学, 医学部, 非常勤講師 (00396871)
OHNUMA Kei  順天堂大学, 医学部, 准教授 (10396872)
Project Period (FY) 2014-04-01 – 2016-03-31
KeywordsMERS感染症 / コロナウイルス / CD26/DPPⅣ / 重症呼吸器感染症 / ヒト化CD26抗体 / CD26単クローン抗体 / アポトーシス / エピトープ
Outline of Final Research Achievements

We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb also significantly inhibited infection. These findings indicate that both 2F9 and humanized Mab are potential therapeutic agents for MERS infection.
MERS infects human bronchial epithelial Calu-3 cells as well as CD26 Jurkat T lymphocyte cells. Unlike severe acute respiratory syndrome (SARS)-CoV, which exclusively infects and releases through the apical route, this virus can do so through either side of polarized Calu-3 cells. Infection results in profound apoptosis irrespective of its production of titers that are lower than those of SARS-CoV. Together, our results provide new insights into the dissemination and pathogenesis of MERS-CoV and may cause in immune defects since it infected in human CD26 T cells.

Free Research Field

医歯薬学

URL: 

Published: 2017-05-10  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi